Aktienanalyse zu IDEXX Laboratories Inc (IDXX)IDXXIDEXX Laboratories Inc

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and provides services primarily for the companion animal veterinary; livestock, poultry and dairy; and water testing industries. It also manufactures and sells human medical point-of-care diagnostic products. Its products and services include point-of-care veterinary diagnostic products, comprised of instruments, consumables, and rapid assay test kits. It also includes veterinary reference laboratory diagnostic and consulting services. It offers practice management systems, software and diagnostic imaging systems and services used by veterinarians. It also offers health monitoring, biological materials testing, laboratory diagnostic instruments, and services used by the biomedical research community. The Company provides diagnostic and health-monitoring products for livestock, poultry, and dairy; and products that test water for certain microbiological contaminants. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).

IDEXX Laboratories is currently a hold. The stock is priced at $554.99, which is below the lowest analyst target of $620 from UBS, indicating potential for upside. However, the RSI is at 49.226, suggesting the stock is neither overbought nor oversold, and the forward P/E ratio is 37.45, which is relatively high, indicating that the stock may be overvalued at this price point. The main risk is the recent downgrade from Barclays, which lowered its price target from $800 to $710, reflecting cautious sentiment in the market.

10 analysts cover IDXX: 6 rate it Buy, 3 Hold and 1 Sell. The average price target is 792.78.